Expect The Cannabis Journal to offer you the latest news on clinical trials, development in the medical world and more. We try to summarize it and give you the links to the trials. All our knowledge has to be shared to make the world a better place!
Medical cannabis is entering a new evidence era, with randomized trials and living systematic reviews clarifying where benefits are real, where they are modest, and what safety tradeoffs matter most for daily life. The latest data show clear antiemetic effects in refractory chemotherapy-induced nausea and vomiting (CINV), small but meaningful pain relief in select populations, and early steps toward precision formulations guided by chemical profiles, all while emphasizing sedation and psychomimetic risks when THC is included.nature+3
Big picture
The 2024 living systematic review update on cannabis and other plant‑based treatments for chronic pain adds new randomized trials yet continues to find at most small, short‑term analgesic benefits with low strength of evidence, reinforcing the need for targeted use rather than blanket claims. Oncology trials in 2024–2025 provide some of the clearest signals, with a phase II/III study demonstrating that a 1:1 THC:CBD oral extract can meaningfully improve refractory CINV control when layered onto guideline prophylaxis, albeit with increased sedation and dizziness.pubmed.ncbi.nlm.nih+1
The latest breakthroughs
A multicenter phase II/III randomized trial found that adding a 1:1 THC:CBD oral extract to standard antiemetic regimens increased complete response in refractory CINV from 8% to 24%, reducing rescue use and nausea, with no study drug–attributed serious adverse events but higher sedation and dizziness rates. In palliative cancer care, a randomized double‑blind trial of 1:1 THC:CBD oil modestly improved pain but did not reduce overall symptom distress, highlighting a tradeoff with psychomimetic effects such as confusion and feeling “high”.ascopubs+1
Machine‑learning analyses of medical cannabis chemical profiles suggest that analgesic outcomes can be predicted from cultivar chemistry beyond placebo expectations, with terpenes like α‑bisabolol and eucalyptol emerging as key predictors, paving a path to precision cannabis therapeutics. In anxiety research, a phase II randomized trial of single‑dose 400 mg CBD in women with metastatic breast cancer did not meet the prespecified primary endpoint but showed lower post‑dose anxiety on a secondary measure with an acceptable short‑term safety profile, underscoring a cautious, evidence‑building trajectory.pubmed.ncbi.nlm.nih+2
Where benefits are clearest today
For chronic pain, aggregated evidence indicates small average benefits over short timeframes, strongest in neuropathic pain, and sensitive to product type and dosing, supporting careful patient selection and monitoring rather than broad substitution for established therapies. In oncology, the antiemetic benefit of adding 1:1 THC:CBD for refractory CINV is now supported by randomized evidence, with clinically relevant gains in complete response balanced by sedation risk.pubmed.ncbi.nlm.nih+1
For multiple sclerosis spasticity, nabiximols (THC:CBD oromucosal spray) continues to show symptom improvement consistent with prior randomized data, with 2024 trials and practice‑based evidence aligning on reductions in spasticity‑related burden. In epilepsy, purified CBD (Epidiolex/Epidyolex) remains supported as add‑on therapy for Lennox‑Gastaut and Dravet syndromes, with 2024 assessments also summarizing efficacy in tuberous sclerosis complex, anchoring the role of CBD in specific refractory epilepsies.pmc.ncbi.nlm.nih+2
Safety and tradeoffs
THC‑containing products commonly cause sedation, dizziness, confusion, and other psychomimetic effects, a pattern replicated in 2024 oncology trials where benefits were balanced by tolerability concerns that matter in daily function. Syntheses of adverse events across cannabis products catalog sedation, dizziness, and anxiety as frequent and typically non‑serious, with risk profiles varying by formulation and THC content, guiding dose titration and counseling on activities like driving.pubmed.ncbi.nlm.nih+3
Population‑level surveillance from Canada shows sizable rates of cannabis‑related adverse events and increased emergency visits post‑legalization, reminding clinicians and patients that real‑world dosing and product variability can amplify risk compared with controlled trials. National updates and evidence digests continue to emphasize standardization, quality control, and risk mitigation to translate trial results safely into practice.davidhammond+1
Opportunities for life
For patients facing chemotherapy, the ability of 1:1 THC:CBD to lift refractory CINV control can reduce breakthrough nausea and rescue medication use, potentially improving appetite, sleep, and adherence to treatment plans when added to guideline care. In advanced cancer, even modest pain reductions may meaningfully affect daily function and comfort, though psychomimetic side effects require shared decision‑making and careful titration.ascopubs+1
A phase II randomized trial now underway aims to prevent chemotherapy‑induced gastrointestinal mucositis symptoms using sublingual CBD plus titrated THC, explicitly targeting multi‑symptom burdens like pain, fatigue, and anorexia to reduce polypharmacy, which could translate into tangible quality‑of‑life gains if efficacy is confirmed. Registry analyses and practice‑based series signal improvements across pain and sleep outcomes in routine care, but these observations need confirmation in longer, well‑blinded randomized trials to ensure durable benefit and safety.pmc.ncbi.nlm.nih+2
Precision formulations and the science of “entourage”
The new chemical‑profile research shows that analgesic response can be predicted using multi‑compound signatures, with terpenes contributing beyond the familiar THC/CBD axis, a finding that could enable product labeling and prescribing based on targeted symptom relief rather than strain names alone. As these models improve, expect clinical trials that stratify by chemical fingerprints and test whether “terpene‑forward” formulations deliver better efficacy‑to‑tolerability ratios than THC‑heavy products, potentially reducing sedation and psychomimetic effects.nature+1
What to expect next
Two national NHS randomized trials beginning in 2025 will test CBD, CBD with low‑dose THC, and placebo across 500 adults and children with refractory epilepsies, generating pivotal evidence on seizure control and broader outcomes like cognition, sleep, and quality of life. U.S. federal research priorities now emphasize better surveillance, exposure measurement, and interventions to mitigate health and safety risks, signaling more rigorous, policy‑relevant cannabis science ahead.epilepsy+1
In Europe’s largest medical market, Germany’s 2024 Cannabis Act has simplified medical access and may accelerate evidence generation and clinician familiarity, with 2025 expected to bring further growth and refinement of reimbursement pathways. Oncology continues to be a locus of innovation, with outcomes research programs and meta‑analyses mapping where cannabis adds value in symptom control and supportive care, while distinguishing promising signals from areas still lacking causal proof.frontiersin+2
Practical guidance for stakeholders
Clinicians should align product selection to indication and tolerability, favoring balanced THC:CBD or CBD‑dominant options where sedation and psychomimetic risks would undermine function, consistent with aggregated safety data and living review conclusions. Patients with refractory CINV may reasonably discuss adding a 1:1 THC:CBD oral extract to guideline antiemetics, factoring in the documented benefits and the need for driving and sedation precautions during titration.pubmed.ncbi.nlm.nih+3
For chronic pain, expectations should be set around small average benefits, close monitoring of function and adverse events, and a willingness to de‑escalate or pivot if goals are not met within realistic timeframes, in step with the 2024 evidence synthesis. As precision chemoprofiles mature, prescribing may shift from “strain” identity to verified chemical signatures linked to response predictions, improving the odds of benefit while reducing side‑effect burden.pubmed.ncbi.nlm.nih+2
The bottom line
Real breakthroughs are emerging in supportive oncology, precision profiling, and targeted epilepsy research, while chronic pain evidence remains modest and safety management—especially around sedation and cognition—defines clinical success. The near‑term opportunities lie in judicious add‑on use where randomized data support benefit, structured titration to manage THC‑related effects, and engagement with trials that can validate multi‑compound formulations for real‑world outcomes. Over the next few years, expect a future shaped by better‑designed RCTs, chemical‑informed products, and policy frameworks that reward standardization and measurable patient‑reported gains.osborneclarke+9
- https://www.nature.com/articles/s43856-025-00996-3
- https://pubmed.ncbi.nlm.nih.gov/40238954/
- https://ascopubs.org/doi/10.1200/JCO.23.01836
- https://pubmed.ncbi.nlm.nih.gov/39694905/
- https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.12020
- https://pubmed.ncbi.nlm.nih.gov/40670615/
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2828077
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10881112/
- https://pubmed.ncbi.nlm.nih.gov/39106541/
- https://www.ncbi.nlm.nih.gov/books/n/ht8269678382079882/
- https://pubmed.ncbi.nlm.nih.gov/38758300/
- https://davidhammond.ca/wp-content/uploads/2023/12/2024-ICPS-Cannabis-Adverse-Events-BMJ-Open-Marquette-et-al.pdf
- https://www.ccsa.ca/sites/default/files/2024-04/Clearing-the-Smoke-on-Cannabis-Medical-Use-of-Cannabis-and-Cannabinoids-2024-Update-en.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11962810/
- https://journals.plos.org/mentalhealth/article?id=10.1371%2Fjournal.pmen.0000390
- https://www.epilepsy.org.uk/news/cannabis-medicine-trials-for-refractory-epilepsy-to-start-in-2025
- https://nida.nih.gov/about-nida/noras-blog/2025/01/new-roadmap-cannabis-cannabis-policy-research
- https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1490621/full
- https://www.osborneclarke.com/insights/future-cannabis-germany-what-expect-after-2025-elections
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11498913/
- https://clinicaltrials.gov/study/NCT06808048?cond=cannabis+medical&viewType=Table&rank=4
- https://awsjournal.org/article/new-classification-of-weed-development-stages-using-machine-learning-methods-radiomics-parameters/
- https://www.sciencedirect.com/science/article/pii/S221342202400074X
